HDYO Research Series: Novartis Update with New Oral Therapy for HD
Channel: HDYO
Date: 21/04/2022

In partnership with HD Buzz, we are excited for our next HDYO Research Series Video. Branaplam was originally designed to treat spinal muscular atrophy, but a new paper outlines how it could hold promise for treating Huntington’s. This oral drug lowers huntingtin protein and will now be tested in a study called VIBRANT-HD.

Read the complete article at https://en.hdbuzz.net/323.

Thanks to our sponsors, uniQure, Neurocrine Biosciences, Sage Therapeutics, and Teva. Follow along each month for more updates.